Abstract Number: 380 • 2016 ACR/ARHP Annual Meeting
Linear Discriminant Analysis of Cultured Fibroblast-like Synoviocytes Identifies 6 Candidate Genes Which Predict Extended Course in Juvenile Idiopathic Arthritis
Background/Purpose: The goal of this project is the identification of informative synovial biomarkers to predict which children with oligoarticular juvenile idiopathic arthritis (JIA) will have…Abstract Number: 381 • 2016 ACR/ARHP Annual Meeting
Calprotectin As a Multipotent Biomarker in Juvenile Idiopathic Arthritis
Background/Purpose: Lack of specific diagnostic, prognostic or response to treatment markers in juvenile idiopathic arthritis (JIA) leads to study new potential markers, as serum calprotectin…Abstract Number: 382 • 2016 ACR/ARHP Annual Meeting
Tumor Necrosis Factor-α -308 a/G Gene Polymorphism in Children with Juvenile Idiopathic Arthritis: Relation to Disease Activity, Damage and Disability
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease of childhood and an important cause of disability. Its cause remains unknown, but…Abstract Number: 383 • 2016 ACR/ARHP Annual Meeting
Potential Biomarkers of Disease Activity in Juvenile Idiopathic Arthritis – Data from the Portuguese Register, Reuma.Pt
, IL6, IL10, IL17 and TNF in patients with JIA, and detect their relation to disease activity. Results: 281 patients, 66% female, mean age 17.3±10…Abstract Number: 384 • 2016 ACR/ARHP Annual Meeting
WITHDRAWN
Abstract Number: 385 • 2016 ACR/ARHP Annual Meeting
Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease
Background/Purpose: Adalimumab (ADA) is a tumor necrosis factor (TNF) inhibitor used for treatment of chronic immune diseases. The safety of ADA treatment in pediatric patients…Abstract Number: 386 • 2016 ACR/ARHP Annual Meeting
Long-Term Efficacy and Safety of Adalimumab in Pediatric Patients with Enthesitis Related Arthritis
Background/Purpose: Enthesitis-related arthritis (ERA) is a JIA category primarily affecting entheses and peripheral joints but can involve the axial skeleton. Disease activity and structural change…Abstract Number: 387 • 2016 ACR/ARHP Annual Meeting
Rituximab Should be Considered in Rheumatoid Factor Negative Poly-Articular Juvenile Idiopathic Arthritis
Background/Purpose: Selective peripheral B-cell depletion by rituximab (RTX) is a relatively recent advance in rheumatic diseases. RTX is an approved treatment in RA. Although very…Abstract Number: 388 • 2016 ACR/ARHP Annual Meeting
Pharmacokinetics, Safety, and Tolerability of Tofacitinib in Pediatric Patients from Two to Less Than Eighteen Years of Age with Juvenile Idiopathic Arthritis
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor that is being investigated for juvenile idiopathic arthritis (JIA). Here, we report the pharmacokinetics (PK), safety, and…Abstract Number: 389 • 2016 ACR/ARHP Annual Meeting
Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Interim Results from the Abatacept in JIA Registry
Background/Purpose: Abatacept is a widely approved and used biologic in children with juvenile idiopathic arthritis (JIA). The purpose of this study was to describe the…Abstract Number: 390 • 2016 ACR/ARHP Annual Meeting
Use, Safety and Efficacy of Zrc 3197, a Biosimilar Candidate for Reference Adalimumab (Humira) from a Tertiary Pediatric Rheumatology Centre in India
Background/Purpose: Reference Adalimumab is not available in our country but biosimilar ZRC 3197 is(1). This is lower priced and as healthcare is primarily self funded…Abstract Number: 391 • 2016 ACR/ARHP Annual Meeting
A Single Centre Experience from India on the Safety and Efficacy of Cipla Etanercept and Intas Etanercept and Its Comparison with Reference Etanercept(Enbrel) in Children with JIA
Background/Purpose: Cost is a major impediment for use of biologic response modifiers (BRMs). Biosimilars/Intended copies, priced at almost half the reference molecule might be the…Abstract Number: 392 • 2016 ACR/ARHP Annual Meeting
Safety and Clinical Response of Weekly Adalimumab in the Treatment of Juvenile Idiopathic Arthritis, Pediatric Chronic Uveitis and Other Childhood Rheumatic Diseases
Background/Purpose: Every other week adalimumab is used to treat juvenile idiopathic arthritis (JIA) and other pediatric rheumatic diseases. It is common for pediatric rheumatologists to…Abstract Number: 393 • 2016 ACR/ARHP Annual Meeting
Association of Sex, Race and Ethnicity on Disease Outcomes in Juvenile Idiopathic Arthritis Patients
Background/Purpose: JIA patients are predominantly non-Hispanic white and studies have shown that race and ethnicity may be associated with worse disease. This study assesses the…Abstract Number: 394 • 2016 ACR/ARHP Annual Meeting
Effect of BMI on Symptoms and Outcomes in Juvenile Idiopathic Arthritis Patients
Background/Purpose: Children with JIA are at risk for cardiovascular disease and obesity compounds this risk. There is limited data on the prevalence of elevated BMI…
